Zur Rose Group: Purchase price payment for medpex acquisition completed early by earn-out settlement
December 27, 2019 at 06:16 am
Share
27.12.2019 - Zur Rose Group AG
Zur Rose Group AG / Key word(s): Financing
Zur Rose Group: Purchase price payment for medpex acquisition completed
early by earn-out settlement
27.12.2019 / 07:00
---------------------------------------------------------------------------
Press release
medpex acquisition:
- Puchase price payment completed early by earn-out settlement
- medpex founders take on leading management positions in Germany segment
- Best-in-class skills at medpex drive ahead growth in market leadership in
Germany
The Zur Rose Group and the sellers of the medpex online pharmacy activities
have agreed to settle the 2019 and 2020 earn-out components, which form part
of the purchase price, at the end of 2019 by making a one-off payment of the
amount estimated in the 2019 interim financial statements. Since the
takeover the founders of medpex have driven ahead the business successfully
and reached the agreed growth targets. medpex has best-in-class skills in
online marketing and technology and forms the ideal complement to the
current strategy and focus on the German market to expand market leadership.
By ending the earn-out early the Zur Rose Group aims to use the expertise of
the founders as quickly as possible for the entire Germany segment. They are
therefore taking on leading management positions in the Germany segment. To
tie them in to the Zur Rose Group they participate in a management share
programme on a considerable scale and will significantly increase their
existing holdings.
Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: ir@zurrose.com, phone: +41 58 810 11 49
Media contact
Lisa Lüthi, Head of Group Communications
Email: media@zurrose.com, phone: +41 52 724 08 14
Agenda
22 January 2020 Sales 2019
19 March 2020 2019 Full-Year Results
16 April 2020 First Quarter Trading Update
23 April 2020 Annual General Meeting
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of
the leading medical wholesalers in Switzerland. With its business model, it
offers high-quality, safe and cost-effective pharmaceutical care and thus
contributes to reducing healthcare costs. It is also characterized by the
continuous further development of digital services in the field of drug
management and actively promotes its positioning as a comprehensive,
integrated cross-service healthcare platform. The creation of added value
and a pronounced patient orientation make the Group an important strategic
partner for service providers, payers and industry.
The Zur Rose Group is internationally present with strong brands, including
Germany's best-known pharmacy brand DocMorris. The company employs over
1,300 people at various locations and generated a turnover of CHF 1,207
million in the 2018 financial year. The shares of Zur Rose Group AG are
listed on the SIX Swiss Exchange (securities number 4261528, ISIN
CH0042615283, ticker ROSE). Further information at zurrosegroup.com
fermer
Attachments
Original document
Permalink
Disclaimer
Zur Rose Group AG published this content on 27 December 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 December 2019 06:15:09 UTC
Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.